September 9, 2025- ZOLL® announced that transvenous phrenic nerve stimulation (TPNS) – the treatment currently available only by the ZOLL remedē® System – is now included in the updated American Academy of Sleep Medicine (AASM) guidelines for treatment of central sleep apnea (CSA).
The AASM recognizes the patient benefits of TPNS, highlighting the improvements in central event indices, oxygen desaturation index, quality of life, and several sleep architecture measures. TPNS is recommended both in primary central sleep apnea and central sleep apnea due to heart failure.
TPNS is the only new therapy added to the guidelines since the last update in 2012. The AASM noted the development of TPNS and additional data on adaptive servo ventilation (ASV) as the primary drivers behind the updated guidelines. TPNS is also one of only two guideline-recommended therapies to show improved clinical outcomes in disease severity, excessive sleepiness, and cardiovascular health.